12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HIV/AIDS vaccine: Phase IIa data

The double-blind, placebo-controlled, U.S. and Peruvian Phase IIa HVTN 205 trial in 300 healthy, uninfected volunteers showed that subjects who received GeoVax's HIV-1 DNA vaccine given as a primer followed by the HIV-1 MVA vaccine given as a booster had significantly greater CD4 T cell responses vs. subjects who received the MVA vaccine without the DNA vaccine (65% vs. 43%, p=0.01). Additionally, CD8 T cell responses were achieved in...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >